A Phase 1 study of the combination of pexidartinib and sirolimus to target tumor-associated macrophages in unresectable sarcoma and malignant peripheral nerve sheath tumors

Gulam A. Manji1,2,*, Brian A. Van Tine3,4,5, Shing M. Lee6, Alex Raufi2,7, Ilenia Pelliciotta2, Angela C. Hirbe3,4,5, Jaya Pradhan2, Andrew Chen6, Raul Rabadan8, and Gary K. Schwartz1,2.

1 Division of Hematology and Oncology, Columbia University Irving Medical Center, and New York Presbyterian Hospital, Herbert Irving Pavilion, New York, NY; 2 Herbert Irving Comprehensive Cancer Center, New York, NY; 3 Department of Medicine, Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO; 4 Division of Pediatric Hematology/Oncology, St. Louis Children’s Hospital, St Louis, MO, 5 Siteman Cancer Center, St. Louis MO. 6 Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York, USA.; 7 Division of Hematology-Oncology, Lifespan Cancer Institute, Warren-Alpert Medical School of Brown University, Providence, RI, USA. 8 Program for Mathematical Genomics, Departments of Systems Biology and Biomedical Informatics, Columbia University, New York, NY, USA

*Corresponding Author
Gulam Abbas Manji, MD/PhD
Division of Hematology and Oncology and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, 161 Fort Washington Avenue, Suite 8-809 New York, NY 10032, USA.
Phone – 212-305-0592
Email: gam2140@cumc.columbia.edu
Manji et al. Pexidartinib and Sirolimus Sarcoma Phase 1

Running Title: Pexidartinib and sirolimus phase 1 to target M2 macrophages in sarcoma.

Key Words: Pexidartinib, sirolimus, MPNST, M2 macrophages, tenosynovial giant cell tumor.

Translational Relevance 243 (limit 250 words)

Word count, Abstract: 238 (limit 250 words)

Word count, Main text: 4384 (limit 5000 words)

Number of Figures/Tables: 3/2 (limit 6 display)

Additional Files:

Supplementary Data –

Two supplementary figures
Two supplementary tables

Funding: FDA-R01 (1R01FD005745 to GAM and GKS) and the study was partly funded by Plexxikon

Prior Presentation: Results of this study were reported as an abstract and poster form (11055) at the American Society of Clinical Oncology Annual Meeting; May 31 through June 4, 2019; Chicago, IL, USA.
Disclosure of Potential Conflict of Interest

GAM - Clinical Trials Funding from Genentech Roche, Merck, Plexxikon, Regeneron, and BioLineRx. Research Funding from Genentech Roche. Consultant for Arcus Biosciences, BioLineRx, and Ipsen. Advisory Board for CEND Pharm including stocks. Stocks ownership for Gilead Sciences. None of those activities have relation to the work in this manuscript.

BVT – Research Grant from Pfizer, Merck, Tacon Pharm and GSK. Consultant for ADRx, Ayala Pharm, Cytokineti, Bayer, Adaptimmune, Bionest Partners, GSK, Intellisphere LLC. Advisory Board for Adaptimmune, Apexigen Inc., Daiichi Sankyo, Deciphera Pharm, Epizyme, GSK, Lilly and Novartis. Board Member at Polaris.

SML – Clinical Trials Funding from Merck and Plexxikon. Consultant for PTC Therapeutics.

AGR – None.

IP – None

ACH – Consultant for Springworks and Astrazenica

JP – None

AC – None

RR – Raul Rabadan is founder of Genotwin and member of the SAB of AimedBio. None of those activities have relation to the work in this manuscript.

GKS – Advisory Board/Consulting for Apexigen, Array, Bionaut, Concarlo, Ellipsis Pharma, Epizyme, GenCirq, LifeRaft Group, Oncogenuity, and OnCusp. Research grants from Astex and stocks from Pfizer.
TRANSLATIONAL RELEVANCE (243/250 words)

Pexidartinib is a novel potent small molecule inhibitor of colony-stimulating factor-1 receptor (CSF-1R) and targets polarization of the pro-tumorigenic M2 tumor associated macrophages (TAMs) to M1. In our preclinical screen, we identified malignant peripheral nerve sheath tumor (MPNST) cell lines to express high levels of activated CSF-1R. Pexidartinib inhibited cell proliferation and tumor growth in an MPNST xenograft model. The addition of sirolimus to pexidartinib resulted in sustained tumor growth suppression and a profound decrease in TAMs compared to mice treated with pexidartinib alone. These results formed the rationale to conduct a first-in-human study to test this combination in heavily treated patients with soft tissue sarcomas (STS). This phase 1 study was conducted using the time-to-event continual reassessment method and demonstrated acceptable safety, tolerability, profound tumor response in tenosynovial giant cell tumor (TGCT) as expected, and prolonged tumor stabilization in pretreated MPNST patients. TGCT is a rare non-aggressive sarcoma subtype involving the synovium, bursa and tendon sheath for which pexidartinib monotherapy has been demonstrated to be effective previously. Analysis of tumor tissue from pre-treatment biopsy and on-treatment resection from two patients with TGCT and one with TSC complex subunit 1 (TSC1)-mutated leiomyosarcoma using multiplex immunofluorescence identified a decline in activated M2 TAMs in all three on-treatment specimens, but not of M1 TAMs or CD8+ T-cells. A phase 2 study testing the combination at the recommended phase 2 dose is ongoing with required pre-treatment and on-treatment biopsies for correlative analysis, including M2 TAM infiltration.
ABSTRACT (238/250 words)

PURPOSE. To evaluate the safety and tolerability in phase 1 first-in-human combination therapy with pexidartinib, an inhibitor of colony-stimulating factor-1 receptor, and sirolimus, an mTOR inhibitor, to target tumor associated macrophage (TAM) polarization in soft tissue sarcomas (STSs).

PATIENTS AND METHODS. This multicenter phase 1 study used the time-to-event continual reassessment method (TITE-CRM) to study the combination of sirolimus, doses ranging from 2-6mg, with pexidartinib, doses ranging from 600-1000mg, both provided continuously on a 28 day cycle, in patients with advanced sarcoma. A total of 24 patients (eight MPNST, three tenosynovial giant cell tumor (TGCT), five leiomyosarcoma and eight with other sarcoma subtypes) were enrolled. The median age was 46 years, 56% were male, and 61% had >2 prior lines of therapy.

RESULTS. The recommended phase 2 dose (RP2D) was 2mg of sirolimus combined with 1000mg of pexidartinib daily. Of the 18 evaluable subjects, five experienced dose-limiting toxicities (2 elevated AST/ALT, 2 elevated sirolimus trough levels, and 1 grade 5 dehydration). Most common grade 2 or higher treatment related adverse events included anemia, fatigue, neutropenia, and lymphopenia. Clinical benefit was observed in 12 out of 18 (67%) evaluable subjects with 3 partial responses (all in TGCT) and 9 stable disease. Tissue staining indicated a decreased proportion of activated M2 macrophages within tumor samples with treatment.

CONCLUSIONS. Pexidartinib can be safely administered with sirolimus. These findings support further investigation of this combination to determine clinical efficacy. Clinicaltrials.gov identifier NCT02584647.
INTRODUCTION

Although soft tissue sarcomas (STSs) constitute less than 1% of all malignancies, there are greater than 60 distinct subtypes. In general, response to cytotoxic chemotherapy is poor and identifying treatments with meaningful clinical benefit in all subtypes is a daunting challenge\(^1,2\). Conversely, identifying shared underlying vulnerabilities within distinct STS subtypes and targeting them as a sub-group is another strategy to identify novel effective treatment options in this rare disease.

A study surveying tissue microarrays of 1242 sarcoma specimens from 24 subtypes revealed that TAMs outnumber TILs across a majority of sarcomas with M2-polarized macrophages (tumor promoting phenotype) representing the majority of TAMs\(^3\). Similarly, analysis of the TCGA sarcoma data set using gene expression signatures, found that M2-polarized TAMs represented a larger proportion of the immune infiltrate compared to M0- or M1- (tumoricidal phenotype) polarized TAMs\(^4\). These results suggest that macrophage polarizing agents may represent a therapeutic opportunity in certain STS subtypes. Mouse and human neurofibromas, benign precursors to MPNSTs, demonstrate substantial TAMs where they account for almost half of neurofibroma cells\(^5\).

Colony-stimulating factor-1 receptor (CSF-1R) is expressed by many monocytes, macrophages, and certain tumor cells; and expression of CSF-1R is associated with poor prognosis in certain cancers\(^6\). The ligand to CSF-1R, colony-stimulating factor-1 (CSF-1) plays a critical role in differentiation, maturation, survival of mononuclear phagocytic cells, activation of the CSF-1/CSF-1R pathway, and contributes to the conversion of TAMs from an M1 to M2 phenotype\(^7\).

We previously screened STS cell lines for potential vulnerability to the CSF-1R axis and found that multiple MPNST cell lines express high levels of activated CSF-1R\(^8\). In a xenograft model of
Manji et al. Pexidartinib and Sirolimus Sarcoma Phase 1

MPNST, we previously demonstrated that oral administration of pexidartinib, a novel small molecule inhibitor of CSF-1R, KIT, and platelet derived growth factor receptor (PDGFR), blocked MPNST cell proliferation \textit{in vitro} and tumor growth \textit{in vivo}. Mechanistic target of rapamycin (mTOR) plays a key role in cell survival and proliferation through AKT signaling. The addition of sirolimus, an mTOR inhibitor, to pexidartinib in our xenograft MPNST model resulted in sustained anti-tumor activity and decreased TAMs in harvested tumor tissue, compared to tumors harvested from mice treated with pexidartinib alone\textsuperscript{8}.

Pexidartinib was approved by the United States (U.S.) Food and Drug Administration (FDA) as monotherapy for symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery\textsuperscript{9}. In contrast, the European Medicines Agency’s advisory group recommended against pexidartinib for patients with TGCT citing limited symptomatic improvement and concern for hepatotoxicity. To date, pexidartinib either alone or in combination has not been evaluated in MPNSTs. This study is the first-in-human combination of pexidartinib with sirolimus and aims to target TAM-M2 polarization based on our preclinical findings. We conducted a multi-institutional phase 1 study using the time-to-event continual reassessment method (TITE-CRM) to evaluate pexidartinib and sirolimus in heavily pretreated patients with advanced STS. The TITE-CRM was selected as it has improved performance compared to the conventional 3+3 design at identifying the true maximum tolerated dose, treating fewer patients at suboptimal doses, allowing the specification of a fixed sample size for the trial, and increased flexibility in the specification of the target toxicity rate\textsuperscript{10}. Moreover, the TITE-CRM can use the patient’s partial information before a complete follow-up is achieved while allowing for a longer toxicity evaluation window beyond the first cycle to account for late onset toxicities. Thus, we can conduct the trial in a continuous fashion without having patients being turned away due to waiting time. The primary aims of this study were to determine safety,
PATIENTS AND METHODS

Patient Eligibility

Eligible patients included those with unresectable pathologically confirmed sarcoma, who were either intolerant to or had progressed on standard of care therapy, with evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 at baseline, with an Eastern Cooperative Oncology Group (ECOG) performance 0 or 1, and adequate organ and bone marrow function. Patients were excluded if they were unable to swallow capsules or if they suffered from hepatobiliary disease. The study was approved by the Columbia University Irving Medical Center and Washington University institutional review board and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. Each patient provided written informed consent.

Study Design

This phase 1, multicenter, open-label clinical trial (ClinicalTrials.gov identifier: NCT02584647) used the TITE-CRM to evaluate safety and to estimate the maximum tolerated dose (MTD) of a first-in-human combination with pexidartinib (PLX3397) and sirolimus in patients with advanced sarcoma.

Enrolled patients were treated with combination therapy at one of five predefined dose levels with sirolimus doses ranging from 2mg to 6mg orally once daily and pexidartinib doses ranging from 600mg to 1000mg total orally daily. The dose combinations were ordered as seen in Fig
Manji et al. Pexidartinib and Sirolimus Sarcoma Phase 1

1A. Treatment was initiated at dose level 2 with 2mg sirolimus oral daily and 400mg pexidartinib oral twice daily. The MTD was defined as the drug combination associated with a target probability of dose limiting toxicity (DLT) of 0.25. A DLT was defined as any grade 4 or higher hematologic toxicity or grade 3 or higher non-hematologic toxicity according to the National Cancer Terminology Criteria for Adverse Events (version 4.03) within 8 weeks. Grade 3 neutropenia with fever, grade 3 thrombocytopenia with significant bleeding, and any circumstance resulting in a dose reduction, which included dose level reduction of sirolimus for persistently elevated trough levels, were also considered DLTs. All patients were required to receive at least 80% of the planned doses of sirolimus and pexidartinib during the DLT period to be considered evaluable for DLT, after which time dose interruptions were allowed for up to 21 days.

Confirmed radiological responses were evaluated by an independent radiologist using RECIST 1.1 every six weeks. Patients, whose disease progressed by RECIST 1.1 but appeared to derive clinical benefit, as determined by the investigator, were allowed to continue on study as per immune-related RECIST (irRECIST). Changes in tumor size was used to evaluate overall response rate (ORR) and progression free survival (PFS). The pharmacokinetic (PK) profile of pexidartinib and sirolimus was determined using drug specific assays.

Statistical Analysis

The TITE-CRM used an empiric dose-toxicity model, a linear weight function and a normal prior distribution on the parameter with mean 0 and variance of 1.34\textsuperscript{11}. The dose toxicity model was calibrated such that the method will eventually select a dose that yields between 18% and 32% DLT\textsuperscript{12}. We imposed a minimum of 2 weeks of observation between successive patients. Patients who discontinued treatment because of disease progression or death without
experiencing a DLT prior to 4 weeks and those who received less than 80% of planned doses were replenished\textsuperscript{13}. Based on simulation studies, a sample size of 24 was initially proposed to obtain probability of correct selection above 60% across a range of possible scenarios. The protocol was amended on 12/27/2017 after enrollment of 17 patients, to recruit 18 patients, to increase probability of correct selection above 53%.

The MTD was estimated using TITE-CRM based on a target toxicity probability of 0.25\textsuperscript{14}. The proportion of DLT was reported along with the final estimates of the probability for DLT based on the TITE-CRM and its 90% probability interval by dose level. Baseline characteristics for evaluable patients were summarized. Median and range for continuous variable, frequency and percentage for categorical variable were reported. Adverse events were reported by type with frequency and percentage for all grade 3 or higher events and for events where more than 20% of patients experienced grade 1 or 2 events. ORR was estimated for the entire cohort and for those assigned to the estimated MTD along with 95% Confidence Interval (CI). Overall survival and PFS were estimated for the entire cohort, for patients treated at the estimated MTD, and for patients with MPNST using the Kaplan Meier estimator. Median OS and PFS were reported with 95% CI if applicable.

**Macrophage and Cytotoxic T-Lymphocyte Analysis in Paired Tumor Specimens**

*Staining and Imaging*—Tumor specimens were stained using Opal\textsuperscript{\texttrademark} multiplex kits, according to the manufacturer’s protocol (PerkinElmer), for CD8 (clone 4B11; Leica, PA0183), CD68 (clone KP1; BioGenex, Am416-5M), HLA-DR (EP96; BioSB, BSB6797), CD163 (clone OTI2G1; Abcam, ab156769), CD206 (clone 15-2; Abcam, ab64693) and CSF1R (clone EPR20754; Abcam, ab229188). Specimens underwent serial staining with primary and secondary antibodies followed by the use of a covalently bound tyramide signal amplification process\textsuperscript{15,16}.
Manji et al. Pexidartinib and Sirolimus Sarcoma Phase 1

**Multispectral Imaging** – Prior to multiplex staining, H&E stained sections of tumor were verified by two independent pathologists with expertise in sarcoma to identify representative areas for multispectral image capture. Representative tumor areas were scanned at 20x magnification with the VECTRA® platform (PerkinElmer) and factored equally into the analysis for each patient. Images from each single-stained and unstained slide was used to create a multispectral library in inForm®. All images were analyzed using inForm® software. DAPI counterstaining was used to differentiate cellular and nuclear compartments, with each associated cytosolic or membrane bound protein detected via presence of a specific stain (CSF1R, CD206, CD8, CD68, CD163, and HLA-DR).

**Image analysis** – All images were analyzed using inForm® software. DAPI counterstaining (Supplemental Fig S2 online only) was used to differentiate cellular and nuclear compartments, with each associated cytosolic or membrane bound protein detected via presence of a specific stain (CSF1R, CD206, CD8, CD68, CD163, and HLA-DR). Cell segmentation was performed using the minimum DAPI signal to accurately locate all cells and adjusted based on splitting, in order to avoid hypersegmentation or hyposegmentation of each nucleus, and adjusting sizes of nuclei to fit both tumor and immune cells (Supplemental Fig S2, B & C). Following this, tissue segmentation was performed by highlighting examples of tumor and non-tumor tissue, and through an iterative process, a computer algorithm capable of "learning" each tissue type, based morphology, was created (Supplemental Fig S2 D). Cells were phenotyped using the phenotyping step of InForm® software. Approximately 10 representative cells for each base variable were chosen to train the phenotyping algorithm: tumor (red), cytotoxic T cells (magenta), and other (blue) (Supplemental Fig S2 E). Finally, each scoreable variable (CSF1R, CD206, CD163, HLA-DR) was scored for intensity again using the InForm® software (Supplemental Fig. S2 F).
Manji et al. Pexidartinib and Sirolimus Sarcoma Phase 1

**qmIF quantification methods** – Batch-processed output files from InForm® were analyzed with an in-house Python script. Cells were categorized by the base phenotype determined by InForm®, as well as a binary +/- for each scored marker (e.g. CD206, HLA-DR) depending on if the intensity exceeded the score threshold. Only cells found in the tumor compartment (as defined by InForm® tissue segmentation) were used. The counts of each cell type for each image were then divided by the total number of cells to get a cellular proportion for each image. These images were grouped by patient and time point (relative to treatment course), taking the mean proportion across replicate images.
RESULTS

Patient Population

From 11/04/2015 to 09/26/2018, a total of 24 patients with advanced sarcoma were enrolled in the study. Six patients were considered non-evaluable (non-adherence: 2; withdrawal of consent on day 4: 1; progression of disease prior to week 4: 2; serious adverse event unlikely to be drug related: 1; of these, one patient died within 4 weeks due to disease progression). Among the 18 evaluable patients, 2 had no tumor assessment and one had tumor assessment after DLT. Baseline characteristics are listed in Table 1. Notably, most patients had >2 prior lines of systemic therapy. Toxicity data from 1 non-evaluable patient was used for determination of the subsequent patient's dose determination as per the TITE-CRM design.

Treatment-Related Toxicity

Overall, the combination pexidartinib and sirolimus had acceptable toxicity with 5 of 18 evaluable patients experiencing DLTs (supplemental, Table S1). DLTs included elevated AST/ALT in 2 patients, elevated sirolimus trough levels in 2 patients, and grade 5 dehydration and cardiac arrest in 1 patient who refused supportive therapy. Elevated AST/ALT and sirolimus trough levels normalized on dose interruption and/or reduction. All 18 evaluable patients experienced treatment-related adverse events (TRAEs). Grade 3 and 4 TRAEs occurred in 7 (39%) patients and 1 (5.6%) patient, respectively (Table 2). One patient experienced a grade 3 elevation in AST/ALT at dose level 5 that normalized after a brief interruption in treatment. Given clinical benefit, the data safety review committee approved resumption of treatment in this patient who was re-challenged at dose level 4 at which AST/ALT remained ≤ grade 1. Two patients required dose reductions (11%), 7 required dose interruptions (39%) of which 3 were due to elevated sirolimus trough levels (17%), and 11 (61%) patients had died. Of the 11
Manji et al. Pexidartinib and Sirolimus Sarcoma Phase 1

patients who had died, one experienced grade 5 dehydration and the remaining 10 patients expired due to disease progression.

Using the TITE-CRM design, we determined that dose level 3 (1000mg oral total daily dose of pexidartinib and 2mg oral daily of sirolimus) to be the recommended phase 2 dose (RP2D) with an estimated toxicity probability of 0.267 with 90% probability interval (0.109, 0.456) (Supplemental, Table S1). The proportion of DLT at each dose level was reported with the final estimates of the probability for DLT based on the TITE-CRM with 90% probability interval as shown in Table S1. The PK profile indicated expected increased levels of pexidartinib and sirolimus with time. Additionally, increased sirolimus doses did not significantly affect pexidartinib levels as depicted in supplementary Fig S1 and Table S2.

Antitumor Activity

For all the evaluable patients by 26 July 2019, the last date of follow-up, no patients remained on therapy. Eleven (61%) and 3 (17%) patients discontinued therapy due to disease progression and intolerance, respectively. In all, 12 of 18 evaluable patients (66.7%; 95% CI: 41.15%, 85.64%) experienced clinical benefit (3 PR and 9 SD; Fig 1B). A durable (≥18 weeks) reduction in target lesions compared to baseline was observed in three (16.7%) patients, all of whom had TGCT (Fig 1). All three patients with localized TGCT (001-01, 001-02, 001-08), which at presentation were not amenable to surgery, underwent limb sparing tumor resections following the combination therapy for 164, 119, and 363 days, respectively. One of the three patients experienced disease recurrence nine months after surgery (001-01), likely due to incomplete disease removal. The other two patients (001-02 and 001-08) with TGCT remain disease free at last follow up for 5 years and 3.5 years, respectively. Nine patients (50%) achieved stable disease, of whom 4 (22%) had confirmed SD and 2 (11.1%) were durable...
Manji et al. Pexidartinib and Sirolimus Sarcoma Phase 1 (MPNST; ≥ 18 weeks). In all, 12 of 18 patients (66.7%; 95% CI: 41.15%, 85.64%) experienced clinical benefit (3 PR and 9 SD; Fig 1). Patient 001-07 remained on study despite PD due to clinical benefit. This patient was found to have stable disease on the third scheduled assessment but ultimately progressed on follow-up scans and came off of study (Fig 1C). Median progression-free survival (mPFS) and overall survival (mOS) for all evaluable patients was 11.6 weeks (95% CI: 6-24.57) and 35.9 weeks (95% CI: non-calculable), respectively (Fig 2A-B). Median PFS at the estimated MTD (dose level 3) for all evaluable patients and those with MPNST was 11.9 weeks (95% CI: 4.29-30) and 18.6 weeks (95% CI: non-calculable), while median OS at dose level 3 for all evaluable patients and those with MPNST was 35.9 weeks (95% CI: non-calculable) and 145.1 weeks (95% CI: non-calculable), respectively (Fig 2C – F).

Of the six MPNST patients, one was NF1-associated (002-11), four were sporadic, and NF1 status of patient 003-02 was not known. Median PFS and mOS for all who received treatment (24 patients) was 9.7 weeks (95% CI: 6-18.57) and 34.6 weeks (95% CI: 10.9-86.3), respectively. While mPFS and mOS at dose level 3 for all who received treatment (12 patients) was 10.9 weeks (95% CI:4.3-22.1) and 34.6 weeks (95% CI: 7.3-145.1), respectively.

**Macrophage and Cytotoxic T-Lymphocyte Tumor Infiltration**

In an effort to determine the effects of the combination of pexidartinib and sirolimus therapy on TAMs within the sarcoma tumor microenvironment, we applied quantitative multiplex immunofluorescence (qmIF) on available pre- and on-treatment tumor tissue. Three patients on study with TGCT achieved tumor response permitting tumor resection. Patient 001-07, diagnosed with *TSC complex subunit 1 (TSC1)*-mutated leiomyosarcoma experienced a malignant small bowel obstruction on week 11 for which she underwent palliative small bowel resection and tumor specimens were collected for analysis. Presence of tumor in each biopsy specimen was confirmed with H&E staining and verified by an expert sarcoma pathologist. Of the four patients with available paired pre- and on-treatment tissue specimens, resected tumor
tissue from patient 001-08 (TGCT) failed to identify neoplastic cells and was not used for TAM quantification. Each tumor tissue was stained with antibodies specific for CD8 (cytotoxic T lymphocytes (CTLs)), CSF-1R and CD163 (tumor cells and macrophages), CD68 (M1 and M2 macrophages), HLA-DR (activated M1 and M2 macrophages), CD206 (M2 macrophages), and DAPI (nuclear stain) (Supplementary, Fig S2 A-F). Representative paired pre- and on-treatment tissue from patient 001-01 is depicted in Fig 3A. Quantification using the multiplex immunofluorescence panel revealed a decrease in mean cellular proportion of activated M2 macrophages in all on-treatment tumor tissues compared to their corresponding pre-treatment biopsies (Fig 3 B&C). Although proportion of activated total macrophages also decreased in all on-treatment tumor tissues, the magnitude of the decline was less compared to that observed for activated M2 macrophages. Moreover, the therapy did not appear to affect M1 or CTL populations (Supplementary, Fig S2 G-J).
DISCUSSION

This phase 1 trial of the combination of pexidartinib and sirolimus demonstrated feasibility and an acceptable safety profile. Pexidartinib and sirolimus resulted in profound and durable tumor responses in patients with TGCT which was previously demonstrated with pexidartinib alone. Our preclinical data indicated that the combination of pexidartinib and sirolimus would result in both greater and more durable responses than pexidartinib alone, even after discontinuing drug therapy. Though the study was not powered or designed to examine this question, the prolonged benefit seen in 2 patients with TGCT who were resected and remain off drug now for over 3.5 and 5 years may indicate a benefit that exceeds pexidartinib alone. This will require future clinical investigation. Pexidartinib in combination with sirolimus resulted in prolonged tumor stabilization (≥18 wks) in 1 of 2 LMS and 3 of 6 MPNST patients all of whom had prior treatments. The clinical benefit observed in MPNST is encouraging and mirrors our preclinical studies in MPNST models, which predicted efficacy with this combination. Acknowledging the limitations of cross-study comparisons and the small number of MPNST patients treated in our study, these results compare favorably to other studies targeting MPNSTs. Combination therapy targeting mTOR and vascular endothelial growth factor (VEGF), with everolimus and bevacizumab, respectively, in advanced MPNST patients demonstrated a clinical benefit rate of 12% with only 3 of 25 patients achieving stable disease for 4 months or longer. Similarly, combination therapy with sirolimus and ganetespib, an Hsp90 inhibitor, in phase 1 resulted in a sustained partial response in one patient, who had LMS, of the 10 evaluable patients. None of the 10 MPNST patients in the phase 2 portion achieved clinical benefit, as defined by the study protocol. The median duration on the phase 2 trial was 8 weeks (4 - 16 weeks), although one patient experienced sustained stable disease by RECIST for 32 weeks after being allowed to continue therapy despite progression per WHO criteria. The mPFS in our study for the evaluable 18 patients was 11.6 weeks and was 11.9 weeks for the nine patients treated at dose...
Manji et al. Pexidartinib and Sirolimus Sarcoma Phase 1

level 3, the RP2D (Fig 2). In comparison, although limited by a small number of patients and preliminary data from a phase 1 study, the five MPNST subjects treated at dose level 3 experienced a mPFS of 18.6 weeks which is encouraging and is consistent with our preclinical experiments which predicted activity in this histology.

The prolonged mOS (35.9 weeks) observed in our patient population is also encouraging and was influenced by the three TGCT subjects, all of whom had a profound response and proceeded to curative surgeries. Two of these patients remain disease free, while one patient experienced local disease recurrence. This patient went on to respond to another anti-CSF-1R investigational agent but discontinued treatment due to poor tolerance. This patient was re-challenged with pexidartinib as standard of care monotherapy and experienced further decrease in size of the left knee mass and continues to derive benefit. The fact that this patient continued to respond to subsequent CSF-1R-targeted therapies suggests that the recurrence was likely due to residual disease rather than the development of resistance to the CSF-1R pathway.

Dosing at the RP2D of pexidartinib (1000mg total daily dose and sirolimus 2mg daily) had an acceptable toxicity profile. Most patients developed liver function abnormalities. AST and ALT were increased in 89% and 61.1%, and of these 5.6% and 11.1% were grade 3, respectively. The proportion of patients experiencing elevated AST and ALT is similar to that reported in the randomized study (ENLIVEN) of 1000mg loading dose daily for two weeks followed by 800mg of total daily dose of pexidartinib versus placebo in TGCT. Monotherapy pexidartinib resulted in an increase in AST and ALT in 88% and 60% patients, respectively and of which 12% and 18% were grade 3 or higher. These results were comparable to those reported in our study and suggest that addition of sirolimus to pexidartinib does not increase the risk of hepatotoxicity. Other common adverse events (>20%) included fatigue, anemia, neutropenia, thrombocytopenia, elevated alkaline phosphatase, anorexia, nausea, diarrhea, and changes in
skin and hair color. These AEs have been previously attributed to pexidartinib or sirolimus individually and no new unexpected AEs were identified.

The tumor microenvironment (TME) is plastic and prone to modulation by neoplastic and stromal cells where inherent signals are manipulated to enhance tumor growth. Reprograming of the CSF-1/CSF-1R axis by tumor cells has been implicated in homing monocytes to the TME, and their differentiation to the pro-oncogenic M2-polarized macrophages. As expected, our interrogation of the macrophage population within paired samples from two TGCT and one LMS patient revealed a decline in the activated M2-polarized macrophages in all three paired tumor samples. The total number of macrophages also declined in on-treatment tumor issue from TGCT patients but not in the LMS patient. There was no association with treatment and M1-polarized macrophages or CTLs suggesting a treatment-specific effect on M2-macrophages. Although the number of samples limit statistical significance, the decline in activated M2-macrophages within the TME in all available paired samples suggests suppression of the CSF-1/CSF-1R axis. However, with the study design we are unable to determine individual contributions of pexidartinib and sirolimus to the overall decline in activated M2-polarized macrophages. Given the prolonged disease stabilization in MPNST and the correlative analysis, a multicenter phase 2 study testing pexidartinib in combination with sirolimus at the RP2D in patients with MPSNT was activated and is currently accruing patients (NCT02584647).

In conclusion, the combination of pexidartinib and sirolimus was generally well tolerated and the RP2D for pexidartinib was 1000mg oral total daily dose and sirolimus was 2mg oral daily. Correlative studies suggest a decline in the activated tumor associated M2-polarized macrophage population indicating that this combination may hold potential to reprogram TAM polarization.
ACKNOWLEDGMENTS

This research was supported by the United States (U.S.) Food and Drug Administration under award number 1R01FD005745 to GAM and GKS, and Plexxikon, Inc.
REFERENCES

2. Worden FP, Taylor JM, Biermann JS, et al: Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol 23:105-12, 2005
14. 2011 CYDFbtCRMCP:


Manji et al. Pexidartinib and Sirolimus Sarcoma Phase 1

Legends

Fig 1. Time to Event Continual Reassessment Method (TITE-CRM) and Antitumor Activity.
A. TITE-CRM was used to estimate the recommended phase 2 dose with the probability of DLT of 0.25. Treatment was initiated at dose level 2. Total daily doses of sirolimus (S) and pexidartinib (P) are indicated on the y-axis in milligrams. Evaluable (blue circle) and non-evaluable patients (gray circle) enrolled sequentially are depicted. Patients who experienced a DLT are depicted separately at the time of the event (red circle). B. Maximal change of tumor size from baseline assessed by an independent radiologist per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (N=16). Percent change from baseline represents the maximal decrease or minimal increase in target lesion(s). C. Change in individual tumor burden over time from baseline as assessed by RECIST 1.1 (N=16). D. Exposure and duration of response per RECIST 1.1 (N=16). Patients with reduction of target lesion(s) of greater than 30% (●), or those between 30% reduction and 20% increase (▲), or those with equal or greater than 20% (■) are depicted. Dose level (DL).

Fig 2. Progression free and overall survival. Kaplan-Meier curves by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for progression free survival (PFS) and overall survival of 18 evaluable patients with advanced sarcoma who were previously treated (A&B); nine patients at dose level 3 (C&D); and five MPNST patients treated at dose level 3 (E&F). Probability of survival is shown at indicated time points and number of patients at risk at indicated time points are shown below the x-axis. CI, confidence interval; NC, non-calculable.

Fig 3. Activated M2 Macrophages in Tumor Tissue. Treatment with pexidartinib and sirolimus resulted in a decrease in both CD206 expressing cells and CD206 and HLA-DR co-expressing cells. A. Pre-treatment (top row) and post-treatment (bottom row) sections obtained from a
patient with TGCT stained with H & E (left column), antisera against CD206 (middle column), and quantitative multiplex immunofluorescence (qmIF) staining of both CD206 and HLA-DR (right column), with pexidartinib plus sirolimus. **B.** Scoring of pre- and post-treatment tumor tissue from a patient with TGCT for CD206 and HLA-DR using inForm™ (Perkin Elmer) scoring of CD206 (red), HLA-DR (green), and CD206+HLA-DR+ (yellow). **C.** Graphs depict non-statistically significant trends in total and activated macrophages (left column) and total and activated M2 macrophages (right column).

**Fig S1. Pharmacokinetics of Pexidartinib and Sirolimus.** Serum concentration of pexidartinib and sirolimus over 6 hours in the combination study.

**Fig S2. Quantitative Multiplex Immunofluorescence (qmIF) Characterization of the Tumor Immune Microenvironment in one Representative Patient.** **A.** Multiplex image of sarcoma (TGCT) tissue stained using qmIF: DAPI (nuclei, blue), CD8 (CTLs, magenta), CD163 (M2 macrophages and tumor, cyan), CSF-1R (macrophages and tumor, Red), CD68 (M1 and M2 macrophages, orange), HLA-DR (activated M1 and M2 macrophages, yellow), CD206 (M2 macrophages, green). **B.** Entire multiplex image shown with DAPI only. Representative steps in analysis from panel A indicating cell segmentation (**C**), tissue segmentation with tumor area depicted in yellow and non-tumor area in white (**D**), phenotyping showing base phenotypes: T cells (magenta), tumor cells (red), and other cells (blue) (**E**), and scoring with representative CD206 scoring for M2 macrophages (green) (**F**).
Table 1. Baseline characteristics of clinical trial participants (N=18)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Number of Patients (range of %)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Median age, years (range)</strong></td>
<td>46.2y (21-68)</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>8 (44.4)</td>
</tr>
<tr>
<td>Male</td>
<td>10 (56.6)</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>10 (55.6)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>4 (22.2)</td>
</tr>
<tr>
<td>African American</td>
<td>2 (11.1)</td>
</tr>
<tr>
<td>Asian</td>
<td>2 (11.1)</td>
</tr>
<tr>
<td><strong>Sarcoma Subtype</strong></td>
<td></td>
</tr>
<tr>
<td>Malignant peripheral nerve sheath tumors</td>
<td>6 (33.3)</td>
</tr>
<tr>
<td>Pigmented villonodular synovitis</td>
<td>3 (16.7)</td>
</tr>
<tr>
<td>Pleiomorphic sarcoma</td>
<td>2 (11.1)</td>
</tr>
<tr>
<td>Leiomyosarcoma</td>
<td>2 (11.1)</td>
</tr>
<tr>
<td>Gastrointestinal stromal tumor</td>
<td>2 (11.1)</td>
</tr>
<tr>
<td>Spindle cell sarcoma</td>
<td>1 (5.6)</td>
</tr>
<tr>
<td>Epithelioid angiomyolipoma</td>
<td>1 (5.6)</td>
</tr>
<tr>
<td>Hemangiopericytoma</td>
<td>1 (5.6)</td>
</tr>
<tr>
<td><strong>Number of Prior Therapies</strong></td>
<td></td>
</tr>
<tr>
<td>0-1</td>
<td>7 (38.9)</td>
</tr>
<tr>
<td>&gt;2</td>
<td>11 (61.1)</td>
</tr>
</tbody>
</table>
Table 2. Number of patients with maximum grade adverse events (N=18).

<table>
<thead>
<tr>
<th>Treatment-Related Adverse Events</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
<th>Grade 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspartate aminotransferase increased</td>
<td>14 (77.8%)</td>
<td>1 (5.6%)</td>
<td>1 (5.6%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anemia</td>
<td>6 (33.3%)</td>
<td>7 (38.9%)</td>
<td>2 (11.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>6 (33.3%)</td>
<td>5 (27.8%)</td>
<td>2 (11.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alanine aminotransferase increased</td>
<td>8 (44.4%)</td>
<td>1 (5.6%)</td>
<td>2 (11.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrophil count decreased</td>
<td>5 (27.8%)</td>
<td></td>
<td>1 (5.6%)</td>
<td>1 (5.6%)</td>
<td></td>
</tr>
<tr>
<td>White blood cell decreased</td>
<td>5 (27.8%)</td>
<td>5 (27.8%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alkaline phosphatase increased</td>
<td>5 (27.8%)</td>
<td>1 (5.6%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anorexia</td>
<td>4 (22.2%)</td>
<td>1 (5.6%)</td>
<td>1 (5.6%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>5 (27.8%)</td>
<td>1 (5.6%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>2 (11.1%)</td>
<td>3 (16.7%)</td>
<td>1 (5.6%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphocyte count decreased</td>
<td>3 (16.7%)</td>
<td>4 (22.2%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>5 (27.8%)</td>
<td>1 (5.6%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Platelet count decreased</td>
<td>4 (22.2%)</td>
<td>1 (5.6%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine increased</td>
<td>3 (16.7%)</td>
<td>1 (5.6%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>3 (16.7%)</td>
<td>1 (5.6%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>5 (27.8%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dehydration</td>
<td></td>
<td>1 (5.6%)</td>
<td></td>
<td>1 (5.6%)</td>
<td></td>
</tr>
<tr>
<td>Upper respiratory infection</td>
<td></td>
<td>1 (5.6%)</td>
<td></td>
<td>1 (5.6%)</td>
<td></td>
</tr>
<tr>
<td>Cardiac arrest</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 (5.6%)</td>
</tr>
</tbody>
</table>
Figure 2

A. All Dose Levels – All Histology

Median PFS: 11.64 weeks (95% CI: 6, 24.57)

B. All Dose Levels – All Histology

Median survival: 35.86 weeks (CI: NC)

C. Dose Level 3 – All Histology

Median PFS: 11.86 weeks (95% CI: 4.29, 30)

D. Dose Level 3 – All Histology

Median survival: 35.86 weeks (CI: NC)

E. Dose Level 3 – MPNST

Median PFS: 18.57 (CI: NC)

F. Dose Level 3 – MPNST

Median survival: 145.14 weeks (CI: NC)
Figure 3

A

<table>
<thead>
<tr>
<th>Pre-treatment</th>
<th>On-treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>H&amp;E</td>
<td>CD206</td>
</tr>
<tr>
<td>M2 Macrophages</td>
<td>Activated M2 Macrophages</td>
</tr>
<tr>
<td>CD206</td>
<td>CD206</td>
</tr>
<tr>
<td>CD206</td>
<td>CD206</td>
</tr>
<tr>
<td>HLA-DR</td>
<td>HLA-DR</td>
</tr>
<tr>
<td>DAPI</td>
<td>DAPI</td>
</tr>
</tbody>
</table>

B

CD206 HLA-DR

C

- Total Macrophages
- M2 Macrophages
- Activated Total Macrophages
- Activated M2 Macrophages

Timepoint:

- PRE PLX
- POST/ON PLX

Mean Cellular Proportion:

- 0.00
- 0.01
- 0.02
- 0.03
- 0.04
- 0.05
- 0.06
- 0.07
- 0.08
- 0.09

Patient:

- 003-01
- 003-02
- 003-07

Downloaded from clincancerres.aacrjournals.org on July 31, 2021. © 2021 American Association for Cancer Research.
Phase 1 study of combination pexidartinib and sirolimus to target tumor associated macrophages in unresectable sarcoma and malignant peripheral nerve sheath tumors.


Updated version

Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-21-1779

Supplementary Material

Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2021/07/27/1078-0432.CCR-21-1779.DC1

Author Manuscript

Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/early/2021/07/27/1078-0432.CCR-21-1779. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.